ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Neuphoria Therapeutics Inc. (NEUP) shows an Average True Range (ATR) of 0.39 and an Enterprise Value of N/A. Its average trading volume over the past 3 months is 32.82K, indicating liquidity. These fundamental metrics provide insight into NEUP's underlying financial health and market activity.
Neuphoria Therapeutics Inc. (NEUP) technical indicators as of August 11, 2025: the SMA 20 is -6.02%, SMA 50 at 1.31%, and SMA 200 at 43.62%. The RSI 14 value is 44.67, suggesting its current momentum. These technical analysis signals help assess NEUP's price trends and potential future movements.
Neuphoria Therapeutics Inc. (NEUP) stock performance overview as of August 11, 2025: The 52-week high is $12.55 (currently -40.8% below), and the 52-week low is $2.12 (currently 249.81% above). Over the past year, NEUP's performance is 15.91%, compared to the S&P 500's 20.13% change.
According to market data, Neuphoria Therapeutics Inc. (NEUP) stock's recent performance metrics show that over the last month, NEUP is -2.24%, with a Year-to-Date (YTD) performance of 116.62%. Over the past year, the stock has seen a 15.91% change. These figures summarize NEUP's price movements across various periods, reflecting its historical returns.
According to current financial data, NEUP stock's P/E (TTM) ratio is 303.14, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for NEUP, including P/S (0.89), P/B (66.88), and P/FCF (33.48), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.